Monday, December 09, 2019 12:53:00 PM
The THOR buyout is impressive, but remember, it's just over $2 billion and they have 30+ million shares outstanding. We have over half a billion shares outstanding, and with the conversions of warrants, etc. we are near a billion. A $2 billion buyout would bring us $2+ in share price, if we're looking for $20, it will take a $20 billion offer unless the company reduces the number of shares.
I certainly don't want a reverse split, but if a partner came in with substantial funds, a share buyback might bring the numbers down somewhat, but we're still probably going to have half a billion or more. If we had the O/S at half a billion, we'd need a $10 billion offer for a $20 share price. It's certainly possible in a couple years, but I don't see it happening next year.
Of course I've left out something that could be very important, emotion. If some major press exposure was given to DCVax-L, major national news, a front page story in the likes of the Wall St. Journal or NY Times, etc no telling how high the stock could go as people see the cheap share prices, and fail to recognize how large the O/S is. If emotion did drive the price to $5, $10, or more, while I typically am not a swing trader, I would change my way of thinking and probably consider establishing a trailing stop loss position in all my shares. I'd raise them as the stock was moving up, and look to buy back in when the market cap was back to the couple billion area, where I believe it belongs after solid news from Phase 3. There is no telling how high emotion can take a stock, years ago a NY Times article on Judah Folkman curing mice took a single digit stock to over $100, it wasn't long before it came back down to earth.
Most here know I've been involved with IMGN essentially since it became public. It's risen to over $40 and fallen to below $1 over all these years. I still believe in it's potential, but today its market cap is back under $1 billion in the belief that a new approved drugs is still years off. The previously approved drug, Kadcyla, has been totally monetized, so no further financial benefits will be seen from it. My point is that success in the clinic can only bring stock success when it brings in substantial and routinely growing revenue. In IMGN's case, the needs for funds now resulted in forfeiting all future fund growth. As much as I dislike dilution, IMGN would have been better off maintaining it's milestone and royalty income through dilution and/or partnerships. NWBO certainly has diluted, but in doing so, it's not given away its intellectual property.
Gary
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • Oct 3, 2024 7:00 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM